• 한국컴퓨터정보학회논문지
• /
• 제21권3호
• /
• pp.65-71
• /
• 2016

To reduce the expenses for development a novel drug, systems biology has been studied actively. Target prediction, a part of systems biology, contributes to finding a new purpose for FDA(Food and Drug Administration) approved drugs and development novel drugs. In this paper, we propose a classification model for predicting novel target genes based on relation between target genes and disease related genes. After collecting known target genes from TTD(Therapeutic Target Database) and disease related genes from OMIM(Online Mendelian Inheritance in Man), we analyzed the effect of target genes on disease related genes based on PPI(Protein-Protein Interactions) network. We focused on the distinguishing characteristics between known target genes and random target genes, and used the characteristics as features for building a classifier. Because our model is constructed using information about only a disease and its known targets, the model can be applied to unusual diseases without similar drugs and diseases, while existing models for finding new drug-disease associations are based on drug-drug similarity and disease-disease similarity. We validated accuracy of the model using LOOCV of ten times and the AUCs were 0.74 on Alzheimer's disease and 0.71 on Breast cancer.

• 제어로봇시스템학회:학술대회논문집
• /
• 제어로봇시스템학회 1994년도 Proceedings of the Korea Automatic Control Conference, 9th (KACC) ; Taejeon, Korea; 17-20 Oct. 1994
• /
• pp.494-497
• /
• 1994

We propose a novel velocity detection method of moving object based on a speckle pattern on the target surface using a self-mixing laser diode (SMLD). By this measurement, it was confirmed that the speckle signal has its waveform independent of the target velocity, and has its averaged frequency directly proportional to the target velocity. So it will be possible to detect the velocity of the target transversely translating against the laser light beam using a compact measuring system.

• 한국군사과학기술학회지
• /
• 제2권2호
• /
• pp.30-39
• /
• 1999

In this paper, we have proposed a novel method which can compose a reflected signal of the underwater target. The synthesis of the reflected signal in the target, the synthesized signal being similar to the characteristics of the reflected signal in the real target, is used the highlight model at the specific points of the target. We suggest the synthesis method of the reflected signal of the target using the pulsewidth variation and each other doppler effect at the highlight point, and compare the composed signal by the proposed method with that by conventional one. Simulation results show that the composed signal using the proposed method and the reflected signal of the real target is similar to the spectral characteristics.

• 대한의생명과학회지
• /
• 제17권1호
• /
• pp.1-5
• /
• 2011

Previously, we have identified 14 putative downstream target genes of Hoxc8 homeoprotein in F9 murine embryonic teratocarcinoma cells through proteomics analysis. Among those, we tested a possibility of a DNA-k type molecular chaperone, Grp78, as a direct downstream target of Hoxc8, by cloning a 2.4 kb upstream region of murine Grp78 into a reporter plasmid and by testing if Hoxc8 can regulate its expression. We observed that Hoxc8 proteins could transactivate the reporter gene, which was affected by small interference RNAs (siRNAs) against to Hoxc8, suggesting that Grp78 is a novel downstream target of Hoxc8 in vivo.

• Bulletin of the Korean Chemical Society
• /
• 제28권10호
• /
• pp.1645-1650
• /
• 2007

This paper describes a racemic and stereoselective synthetic route for a novel cyclohexenyl carbocyclic adenine analogue. The required stereochemistry of the target compound was controlled using a stereoselective glycolate Claisen rearrangement followed by α-chelated carbonyl addition. The introduction of 6-chloropurine was achieved using Mitsunobu conditions, and further modifications of the corresponding heterocycle gave the target cyclohexenyl nucleoside.

• Biomolecules & Therapeutics
• /
• 제28권2호
• /
• pp.172-183
• /
• 2020

Phosphoinositide 3-kinase (PI3K) is considered as a promising therapeutic target for rheumatoid arthritis (RA) because of its involvement in inflammatory processes. However, limited studies have reported the involvement of PI3KC2γ in RA, and the underlying mechanism remains largely unknown. Therefore, we investigated the role of PI3KC2γ as a novel therapeutic target for RA and the effect of its selective inhibitor, PBT-6. In this study, we observed that PI3KC2γ was markedly increased in the synovial fluid and tissue as well as the PBMCs of patients with RA. PBT-6, a novel PI3KC2γ inhibitor, decreased the cell growth of TNF-mediated synovial fibroblasts and LPS-mediated macrophages. Furthermore, PBT-6 inhibited the PI3KC2γ expression and PI3K/AKT signaling pathway in both synovial fibroblasts and macrophages. In addition, PBT-6 suppressed macrophage migration via CCL2 and osteoclastogenesis. In CIA mice, it significantly inhibited the progression and development of RA by decreasing arthritis scores and paw swelling. Three-dimensional micro-computed tomography confirmed that PBT-6 enhanced the joint structures in CIA mice. Taken together, our findings suggest that PI3KC2γ is a therapeutic target for RA, and PBT-6 could be developed as a novel PI3KC2γ inhibitor to target inflammatory diseases including RA.

• 제어로봇시스템학회논문지
• /
• 제20권1호
• /
• pp.29-36
• /
• 2014

In this paper, a novel MBE (Model Based target size Estimator) is presented for SDIIR (Strap Down Imaging Infrared) seekers. The target tracking requires the target size information for which residual range between target and missile should be provided. Unfortunately, in general, the missile with passive sensor such as IIR (Imaging Infrared), CCD (Coupled Charging Device) cannot obtain range information. To overcome the problem, the proposed method enables the SDIIR seeker to estimates target size by using target size model and track the target. The performance of proposed method is tested at IIR target tracking of target intercept scenario. The experiment results show that the proposed algorithm has the relatively good performance.

• 한국컴퓨터정보학회논문지
• /
• 제22권12호
• /
• pp.55-61
• /
• 2017

In this paper, we propose a novel tracking method using target separation and detection that are based on discriminative correlation filter (DCF), which is studied a lot recently. 'Retainability' is one of the most important factor of tracking. There are some factors making retainability of tracking worse. Especially, fast movement and occlusion of a target frequently occur in image data, and when it happens, it would make target lost. As a result, the tracking cannot be retained. For maintaining a robust tracking, in this paper, separation of a target is used so that normal tracking is maintained even though some part of a target is occluded. The detection algorithm is executed and find new location of the target when the target gets out of tracking range due to occlusion of whole part of a target or fast movement speed of a target. A variety of experiments with various image data sets are conducted. The algorithm proposed in this paper showed better performance than other conventional algorithms when fast movement and occlusion of a target occur.

• 한국환경성돌연변이발암원학회지
• /
• 제22권4호
• /
• pp.236-242
• /
• 2002

Using agarose-coupled methotrexate, we have successfully isolated two proteins, which have strong interactions with methotrexate. The two proteins were analyzed by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry and identified as carbamoyl-phosphate synthetase 2 and phosphoribosylglycinamide formyltransferase, respectively. Interestingly, both of these two proteins are essential key enzymes in nucleotide biosynthetic pathways, like dihydrofolate reductase, a well-known methotrexate target. We confirmed the specificity of their interactions between methotrexate and two target proteins by the methods of competition binding assay, which were followed by western blotting using antibody against carbamoyl-phosphate synthetase 2 and phosphoribosylglycinamide formyltransferase, respectively. Moreover, we could observe that carbamoyl-phosphate synthetase 2 is overexpressed in methotrexate-resistant MOLT-3 cells comparing with control MOLT-3 cells. This result indicates that carbamoyl-phosphate synthetase 2 may be a novel target of methotrexate in cancer therapy. We propose that chemical proteomics can be a powerful technique to identify target proteins of a chemical.

• Oncology Letters
• /
• 제17권3호
• /
• pp.2576-2582
• /
• 2019

Gestational trophoblastic disease (GTD) is an unusual disease occurring in pregnancy that originates from abnormal trophoblastic cells and comprises a group of diseases with different properties of invasion, metastasis and recurrence. The GTD group includes hydatidiform moles and gestational trophoblastic neoplasms (GTNs), with GTNs being divided into invasive moles, choriocarcinoma, placental site trophoblastic tumors and epithelioid trophoblastic tumors. The present review focuses on current effective treatments for GTD, including conventional and novel promising direct enzyme prodrug therapies (DEPTs). Conventional therapies, such as chemotherapy and hysterectomy, are currently used in a clinical setting; however, the use of diverse DEPTs, including antibody-DEPT and gene-DEPT is also being attempted to cure GTNs. In addition, gene delivery tools using genetically engineered neural stem cells (NSCs) are presently being examined for the treatment of GTNs. The tumor-tropism of NSCs by chemoattractant factors is a unique characteristic of these cells and can serve as a vehicle to deliver anticancer agents. Previous studies have demonstrated that injection with NSC-expressing suicide genes into xenograft animal models has a significant inhibitory effect on tumor growth. Stem cells can be genetically engineered to express anticancer genes, which migrate to the metastatic sites and selectively target cancer cells, and are considered to effectively target metastatic GTNs. However, the safety issue of stem cell therapy, such as tumorigenesis, remains a challenge. Novel therapies comprising a combination of conventional and novel promising treatments are anticipated to be definitive treatments for metastasized and/or recurrent patients with GTNs.